[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics

American Journal of Psychiatry

Volumn 153, Issue 2, 1996, Pages 183-190

  Klemm, Edzard ^a   Grünwald, Frank ^a   Kasper, Siegfried ^a   Menzel, Christian ^a   Broich, Karl ^a   Danos, Peter ^a   Reichmann, Karl ^a   Krappel, Christian ^a   Rieker, Olaf ^a   Briele, Bernd ^a   Hotze, Andreas L ^a   Möller, Hans Jürgen ^a   Biersack, Hans Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PYRROLIDINE DERIVATIVE; BENPERIDOL; BIPERIDEN; CARBAMAZEPINE; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LITHIUM; LORAZEPAM; PERAZINE; PIMOZIDE; PROMETHAZINE; REMOXIPRIDE; SULPIRIDE; THIORIDAZINE;

ADULT; ARTICLE; COMPARATIVE STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; FEMALE; FRONTAL LOBE; HUMAN; MALE; METABOLISM; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; DIAGNOSTIC IMAGING; DOPAMINERGIC SYSTEM; HYPERACTIVITY; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; CONTRAST MEDIA; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRONTAL LOBE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0029664735     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.2.183     Document Type: Article

References (49)

1. Crow TJ: Molecular pathology of schizophrenia: more than one disease process? Br Med J 1980; 280:66-68
2. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-719
3. Ungerstedt U: Stereotaxic mapping of the monoamine pathways in rat brain. Acta Physiol Scand Suppl 1971; 367:1-48
4. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC: Molecular cloning and characterisation of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347:146-151
5. Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350:610-614
6. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G: Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991; 350:614-619
7. Wagner HH Jr, Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravert HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuhar MJ: Imaging dopamine receptors in the human brain by positron tomography. Science 1983; 221: 1264-1266
8. Farde L, Hall H, Ehrin E, Sedvall G: Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231:258-261
9. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B: Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl) 1989; 99:463-472
10. 18F)-fluoroethyl)-spiperone: a novel ligand for cerebral dopamine receptor studies with PET. Life Sci 1987; 40:81-88
11. Kung HF, Kasliwal R, Pan S, Kung MP, Mach RH, Guo YZ: Dopamine D2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl) methyl] benzamide. J Med Chem 1988; 31:1039-1043
12. Brucke T, Tsai YF, McLellan C, Singhanyom W, Kung HF, Cohen RM, Chiueh CC: In vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([125I]-IBZM): a potential imaging ligand for D-2 dopamine receptors in SPECT. Life Sci 1988; 42:2097-2104
13. Kung HF, Alavi A, Chang W, Kung M-P, Keyes JW Jr, Velchik MG, Billings J, Pan S, Noto R, Rausch A, Reilley J: In vivo imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 1990; 31:573-579
14. Haase H-J: Therapie mit Psychopharmaka und anderen seelisches Befinden beeinflussenden Medikamenten, 4th ed. Stuttgart, Germany, Schattauer, 1977
15. Davis JM: Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974; 11:65-69
16. Kay SR, Opler ER, Fiszbein A: Positive and Negative Syndrome Scale (PANSS) Rating Manual. New York, Albert Einstein College of Medicine, Montefiore Schizophrenia Research Unit, 1986
17. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
18. 3H-dopamine binding associated with dopamine receptors in calf brain membranes. Mol Pharmacol 1976; 12:800-812
19. Keller HH, Schaffner R, Haefely W: Interaction of benzodiazepines with neuroleptics at central dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 1976; 294:1-7
20. 2 dopamine and muscarine cholinergic receptors in rat striatum. J Pharmacol Exp Ther 1988; 244: 987-993
21. 123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease. Eur J Radiol 1991; 12:182-186
22. Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Küfferle B, Müller C, Deecke L: Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatrie disorders. J Cereb Blood Flow Metab 1991; 11:220-228
23. Camps M, Cortes R, Gueye B, Probst A, Palacios JM: Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience 1989; 28:275-290
24. Brücke T, Roth J, Podreka I, Strobl R, Wenger S, Asenbaum S: Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics (letter). Lancet 1992; 339:497
25. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NPLG, Kerwin RW: Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340:199-202
26. Grünwald F, Danos P, Kasper S, Reichmann K, Briele B, Klemm E, Rieker O, Shih W-J, Möller H-J, Biersack H-J: IBZM SPECT in psychiatric diseases, in Radioactive Isotopes in Clinical Medicine and Research: Proceedings of the 20th International Symposium. Edited by Höfer R, Bergmann H, Sinzinger H. New York, Schattauer, 1993
27. 123I-markiertem lodobenzamid (IBZM): Aspekte der semiquantitativen Auswertung. Nuklearmedizin 1993; 32:227-230
28. Drapper N, Smith H: Applied Regression Analysis. New York, John Wiley & Sons, 1981
29. Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192:481-483
30. Peroutka SJ, Snyder SH: Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 1980; 137:1518-1522
31. Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
32. Cambon H, Baron JC, Boulenger JP, Loc'h C, Zarifian E, Maziere B: In vivo assay for neuroleptic receptor binding in the striatum: positron tomography in humans. Br J Psychiatry 1987; 151:824-830
33. Stille G, Hippius H: Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin). Pharmacopsychiatry (Berl) 1971; 4: 182-191
34. Kane J, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
35. Lewander T, Westerburgh S-E, Morrison D: Clinical profile of remoxipride - a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr Scand Suppl 1990; 358:92-98
36. Hebenstreit GF, Laux G, Schubert H, Beckmann H, Amman J, Bunse J, Eikmeier G, Geretsegger C, Kanitz D, Kanzow WT, König P, Mair M, Mayr H, Platz T, Rittmannsberger H, Schony HW, Struck M, Viski-Hanka Z, Wibmer M, Zöchling R: A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia. Pharmacopsychiatry (Berl) 1991; 24:153-158
37. Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K: Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatr Scand Suppl 1990; 358:27-36
38. Ogren S-O, Florvall L, Hall H, Magnusson O, Ängeby-Möller K: Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr Scand Suppl 1990; 358:21-26
39. Farde L, von Bahr C: Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET. Acta Psychiatr Scand Suppl 1990; 358:67-71
40. Coward DM, Imperato A, Urwyler S: Biochemical and behavioural properties of clozapine. Psychopharmacology (Berl) 1989; 99:S6-S12
41. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25:390-392
42. 18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm Gen Sect 1991; 86:163-173
43. Broich K, Alavi A, O'Brien CP, Galloway S, Mozley D: Imaging of dopamine D2 receptors with 123 I-IBZM in normal controls with escalating doses of haloperidol (abstract). J Nucl Med 1992; 33:898
44. Farde L, Wiesel F-A, Halldin C, Sedvall G: Central D2-dopamine receptor occupancy in schizophrenic patients treated with anti-psychotic drugs. Arch Gen Psychiatry 1988; 45:71-76
45. Smith M, Wolf AP, Brodie JD, Arnett CD, Barouche F, Shiue CY, Fowler JS, Russell JAG, MacGregor RR, Wolkin A, Angrist B, Rotrosen J, Peselow E: Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatry 1988; 23: 653-663
46. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, Fowler J, Cooper TB: Dopamine receptor occupancy and plasma haloperidol levels (letter). Arch Gen Psychiatry 1989; 46: 482-484
47. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue C-Y, Cooper TB, Brodie JD: Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146:905-908
48. 76Br]bromospiperone in untreated schizophrenic patients. Am J Psychiatry 1990; 147: 44-50
49. 11C]raclopride. Arch Gen Psychiatry 1990; 47:213-219